Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review.

Edwards, Christopher J; Kiely, Patrick; Arthanari, Subhashini; Kiri, Sandeep; Mount, Julie; Barry, Jane; Mitchell, Catherine R; Field, Polly; Conaghan, Philip G

Edwards, Christopher J; Kiely, Patrick; Arthanari, Subhashini; Kiri, Sandeep; Mount, Julie; Barry, Jane; Mitchell, Catherine R; Field, Polly; Conaghan, Philip G.

Afiliação

Edwards CJ; NIHR Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton.
Kiely P; Rheumatology Department, St George's University Hospital NHS Foundation Trust, London, UK.
Arthanari S; SAMETA (South Asia, Middle East, Turkey and Africa), Eli Lilly (Singapore) Pte Ltd, Singapore.
Kiri S; Health Outcomes and HTA Department.
Mount J; Global Patient Outcomes and Real Word Evidence (GPORWE) International.
Barry J; Medical Affairs, Eli Lilly and Company Ltd, Basingstoke.
Mitchell CR; Value Demonstration Practice, Oxford PharmaGenesis Ltd, Oxford.
Field P; Value Demonstration Practice, Oxford PharmaGenesis Ltd, Oxford.
Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.

Rheumatol Adv Pract ; 3(1): rkz002, 2019.

Article em En | MEDLINE | ID: mdl-31431990

Palavras-chave

disease progression; moderate disease activity; prognostic factors; rheumatoid arthritis; systematic review

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Rheumatol Adv Pract Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google